RVNC Key Statistics, Chart & Performance
The current stock price of RVNC is 3.65 USD. In the past month the price increased by 5.19%. In the past year, price decreased by -38.24%.
RVNC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About RVNC
Company Profile
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 597 full-time employees. The company went IPO on 2014-02-06. The firm's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. The company has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The firm has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Company Info
REVANCE THERAPEUTICS INC
1222 Demonbreun Street, Suite 2000
Nashville TENNESSEE 37203 US
CEO: Mark J. Foley
Employees: 597
Phone: 16157247755
REVANCE THERAPEUTICS INC / RVNC FAQ
What does RVNC do?
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 597 full-time employees. The company went IPO on 2014-02-06. The firm's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. The company has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The firm has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
What is the current price of RVNC stock?
The current stock price of RVNC is 3.65 USD. The price increased by 0.27% in the last trading session.
What is the dividend status of REVANCE THERAPEUTICS INC?
RVNC does not pay a dividend.
What is the ChartMill technical and fundamental rating of RVNC stock?
RVNC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for RVNC stock?
15 analysts have analysed RVNC and the average price target is 5.25 USD. This implies a price increase of 43.76% is expected in the next year compared to the current price of 3.65.
Can you provide the number of employees for REVANCE THERAPEUTICS INC?
REVANCE THERAPEUTICS INC (RVNC) currently has 597 employees.
What is the next earnings date for RVNC stock?
REVANCE THERAPEUTICS INC (RVNC) will report earnings on 2025-03-04, after the market close.
RVNC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RVNC. When comparing the yearly performance of all stocks, RVNC is a bad performer in the overall market: 86.55% of all stocks are doing better.
RVNC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVNC. RVNC has a bad profitability rating. Also its financial health evaluation is rather negative.
RVNC Financial Highlights
Over the last trailing twelve months RVNC reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS increased by 53.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RVNC Forecast & Estimates
15 analysts have analysed RVNC and the average price target is 5.25 USD. This implies a price increase of 43.76% is expected in the next year compared to the current price of 3.65.
For the next year, analysts expect an EPS growth of 57.03% and a revenue growth 12.8% for RVNC